Holen Sie sich die Stockscreener-App
471.29
1.48%
-6.836
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Quadrature Capital Ltd Boosts Vertex Pharmaceuticals Stake - National Today
Is Vertex Pharmaceuticals (VRTX) Pricing In Too Much Optimism After Recent Share Gains? - simplywall.st
Connor Clark & Lunn Investment Management Ltd. Acquires 14,706 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
CreativeOne Wealth LLC Trims Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma (NASDAQ:VRTX) Market Focus Builds Across Nasdaq Index - Kalkine Media
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo! Finance Canada
Vertex Pharmaceuticals (VRTX) Sees Target Price Raised by Truist Securities | VRTX Stock News - GuruFocus
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, Truist Financial Analyst Says - MarketBeat
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc - Yahoo Finance
Vertex Pharmaceuticals Shares Sold by Schroder Investment Management - National Today
Vertex (VRTX) Moves 8.3% Higher: Will This Strength Last? - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Schroder Investment Management Group - MarketBeat
Van ECK Associates Corp Has $58.38 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex preps FDA filing for IgAN drug after phase 3 readout - pharmaphorum
S&P 500 Dips 0.21% as Vertex Pharmaceuticals Soars 8.31% Amid Market Struggles - Markets Mojo
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
Richard Bernstein Advisors LLC Sells 4,059 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
DE Burlo Group Inc. Sells 43,740 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Kidney Trial Success Opens Door To New Autoimmune Franchise - simplywall.st
Blair William & Co. IL Reduces Vertex Pharmaceuticals Stake - National Today
Vertex Pharmaceuticals Joins Elite List Of Stocks With 95-Plus Composite Rating - Investor's Business Daily
Bank of Montreal Can Has $164.28 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Narrow-Moat Vertex's Positive Data for Povetacicept Support Diversification Beyond Core CF Franchise - Morningstar
Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today - Yahoo Finance
Vertex Pops On 'Remarkable' Results For Chronic Kidney Disease Drug - Investor's Business Daily
Vertex Pharmaceuticals Stock Jumps with Positive Drug Pipeline News - timothysykes.com
Vertex Pharmaceuticals Hits Milestone with Povetacicept Data, Shares Surge - StocksToTrade
These Stocks Are Today’s Movers: BioNTech, NIO, Centene, Vertex, Paramount, Rivian, Occidental, and More - Barron's
Vertex Just Reported Trial Results for a Kidney Drug. What It Means for the Stock. - Barron's
Vertex Pharmaceuticals (VRTX) Receives Rating Update and Price T - GuruFocus
Key facts: Vertex Pharmaceuticals reports positive trial results; firms raise price targets - TradingView
Here’s Why Vertex Pharmaceuticals Stock (VRTX) Is Up 10% Today - TipRanks
Vertex Pharma to Seek Speedy FDA Approval for Kidney Disease Drug From $4.9B Acquisition - MedCity News
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Up by 8.03% on Mar 10: What Signal Does It Send? - TradingKey
Vertex to seek approval of IgAN drug after Phase III success - Clinical Trials Arena
Vertex Pharmaceuticals Soars on Promising Phase 3 Trial Results for Povetacicept - GuruFocus
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $596.00 Price Target at Morgan Stanley - MarketBeat
VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study - Finviz
This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results - Investopedia
Oil Crashes 10%, Stocks Rebound On Trump End-Of-War Signals: What's Moving Markets Tuesday? - Benzinga
Vertex Pharmaceuticals (VRTX) Rating Maintained, Price Target Raised by Morgan Stanley | VRTX Stock News - GuruFocus
Vertex filing BLA for ‘best-in-class’ IgAN drug on Rainier win - BioWorld MedTech
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $598.00 Price Target at Bank of America - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Trading 9.9% Higher Following Analyst Upgrade - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $585.00 at Citigroup - MarketBeat
Vertex Pharmaceuticals (VRTX) Receives New Analyst Price Target Increase | VRTX Stock News - GuruFocus
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Benzinga
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals - Benzinga
Jefferies Initiates Coverage on Vertex Pharmaceuticals (VRTX) wi - GuruFocus
Truist Securities Adjusts Price Target on Vertex Pharmaceuticals to $525 From $490, Maintains Buy Rating - marketscreener.com
Vertex Ratchets Up Competition In IgAN With Povetacicept Phase III Win - Citeline News & Insights
Vertex Pharmaceuticals stock surges 6% on kidney drug trial win By Investing.com - Investing.com Canada
Why Is Vertex Pharmaceuticals Stock Soaring Tuesday?Vertex Pharmaceuticals (NASDAQ:VRTX) - Benzinga
Vertex Pharmaceuticals (NASDAQ:VRTX) Coverage Initiated at Jefferies Financial Group - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $600.00 at Oppenheimer - MarketBeat
Vertex's $4.9B bet nears payoff with important milestone - NBC Boston
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
VRTX: HC Wainwright & Co. Raises Price Target, Maintains Buy Rat - GuruFocus
Capital World Investors Trims Vertex Pharmaceuticals Stake - National Today
Deep Dive Into Vertex Pharmaceuticals Stock: Analyst Perspectives (16 Ratings) - Benzinga
Capital Research Global Investors Increases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex drug cuts proteinuria in Phase III IgA nephropathy trial - The Pharmaletter
Capital International Inc. CA Buys 16,108 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Capital World Investors Has $10.15 Billion Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Capital International Sarl - MarketBeat
Capital International Ltd. CA Has $47.50 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Capital International Investors Has $1.84 Billion Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
S&P 500 Futures Steady in Premarket Trading; Vertex Pharmaceuticals, UFP Industries Lead - Barron's
Vertex’s Nephropathy Asset Delivers ‘Strong’ Late-Stage Data, Clears Path to FDA - BioSpace
Russell Investments Group Ltd. Raises Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Jefferies Financial Group Cuts Vertex Pharmaceuticals Stake - National Today
Jefferies initiates Vertex stock with buy rating on cystic fibrosis strength - Investing.com
Vertex Pharmaceuticals (VRTX) Gains on Positive Trial Results - GuruFocus
Vertex Pharmaceuticals (VRTX) Shares Rise on Promising Phase 3 T - GuruFocus
Oppenheimer raises Vertex stock price target on kidney drug data - Investing.com
Vertex's $4.9B kidney disease bet hits key milestone - The Business Journals
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):